Who are Capsaicin 0.1% Cream's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cannabidiol oral oil, dl-Methylphenidate plus Cannabidiol, MediCabilis CBD Oil, Acetaminophen IV/PO, CBD, Qutenza Patch.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capsaicin-0-1-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Capsaicin 0.1% Cream — Competitive Intelligence Brief

Capsaicin 0.1% Cream (Capsaicin 0.1% Cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical analgesic. Area: Dermatology.

phase 2 Topical analgesic TRPV1 Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Capsaicin 0.1% Cream (Capsaicin 0.1% Cream) — Henry Ford Health System. Activates TRPV1 receptors to reduce pain

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Capsaicin 0.1% Cream TARGET	Capsaicin 0.1% Cream	Henry Ford Health System	phase 2	Topical analgesic	TRPV1
Cannabidiol oral oil	Cannabidiol oral oil	Hôpital le Vinatier	marketed	Cannabinoid	Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors)
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Acetaminophen IV/PO	Acetaminophen IV/PO	The University of Texas Health Science Center, Houston	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes; possibly TRPV1 and other pain pathways
CBD	CBD	Stero Biotechs Ltd.	marketed	Cannabinoid	5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric)
Qutenza Patch	Qutenza Patch	M.D. Anderson Cancer Center	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical analgesic class)

Bayer · 1 drug in this class
EpiCept Corporation · 1 drug in this class
Express Specialty Pharmacy · 1 drug in this class
Georg Kägi, MD · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Johnson & Johnson Consumer and Personal Products Worldwide · 1 drug in this class
NeurogesX · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capsaicin 0.1% Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/capsaicin-0-1-cream. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab